September 21, 2017 / 11:47 AM / 7 months ago

BRIEF-Provention Bio announces licensing agreements with Janssen for two clinical-stage immunology assets

Reuters Staff

1 Min Read

Sept 21 (Reuters) - Provention Bio Inc

* Provention Bio announces licensing agreements with Janssen for two clinical-stage immunology assets

* Provention Bio says ‍entered into agreements with Janssen Pharmaceutica NV, Janssen Sciences Ireland UC to in-license 2 clinical-stage assets

* ‍Provention Bio -PRV-6527 to be studied in phase 2a POC clinical trial in Crohn’s disease,for which Provention anticipates initiating enrollment in H1 2018 Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.